Early buyers will receive 10% customization on this report.
Industry Dynamics:
Increasing prevalence of chronic diseases, increasing demand for biologics, technological advancements, and new product launches are some of the major factors driving the growth of the drug delivery technology market.
Furthermore, self-administration & home care and rising demand for biosimilars and generic drugs offer significant growth opportunities for player operating in the market. On the other hand, risk of needle-stick injuries and side effects of drugs may restraint the growth of the market.
North America is projected to dominate the market in 2016, with the U.S. accounting for a major share. However, Asia is expected to grow at the highest CAGR during the forecast period. This growth can be attributed to investments by major companies in the area of R&D activities. Also, this region has low costs of labor and clinical trials, which has further served to draw market players to Asia.
Apart from the comprehensive geographical analysis, product analysis, and market sizing; this report also provides a competitive landscape that covers the growth strategies adopted by industry players in the last three years. In addition, the company profiles comprise basic views on the key players and their product portfolios, developments, and strategies adopted.
The drug delivery technology market is highly competitive market with various players. Prominent players in this market include Johnson & Johnson, Inc. (U.S.), F. Hoffman-La Roche (Switzerland), Merck & Co., Inc. (U.S.), Bayer AG (Germany), Pfizer, Inc. (U.S.), Novartis AG (Switzerland), 3M Company (U.S.), Becton, Dickinson and Company (U.S.), GlaxoSmithKline plc, (U.K.), Sanofi (France), and Antares Pharma, Inc. (U.S.).
Target Audience:
• Drug Delivery Technology Manufacturers
• Public and Private Physicians
• Healthcare Institutions (Medical Data Centers)
• Research & Clinical Laboratories
• Distributors and Suppliers of Drug Delivery Technologies
• Health Insurance Payers
• Market Research and Consulting Firms
About MarketsandMarkets™:
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
